SEARCH

SEARCH BY CITATION

References

  • 1
    Schrier RW, Abdullah JG, Weinberger HH, Abraham WT. Therapy of heart failure. Kidney Int 2000; 57: 141825.
  • 2
    Brater DC. Diuretic therapy. New Engl J Med 1998; 339: 38795.
  • 3
    Van Zweiten PA. Neuroendocrine effects of diuretics in heart failure. Br Heart J 1994; 72 (Suppl.): 513.
  • 4
    Cosin J, Diez J. Effects of type of diuretic on mortality in patients with chronic congestive heart failure. Eur J Heart Failure 2000; 2 (Suppl. 2): 201.
  • 5
    Channer KS, McLean KA, Lawson-Matthew P, Richardson M. Combination diuretic therapy treatment in severe heart failure: a randomised controlled trial. Br Heart J 1994; 71: 14650.
  • 6
    Smith GL, Vaccarino V, Kosiborod M et al. Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? J Card Fail 2003; 9: 1325.
  • 7
    Braunschweig F, Linde C, Eriksson MJ, Hofman-Bang C, Ryden L. Continuous haemodynamic monitoring during withdrawal of diuretics in patients with congestive heart failure. Eur Heart J 2002; 23: 5969.
  • 8
    Stewart S, Marley JE, Horowitz JD. Effects of a multidisciplinary home based intervention on unplanned readmissions and survival among patients with chronic congestive heart failure: a randomised controlled study. Lancet 1999; 354: 107783.
  • 9
    Broadley AJM, Marshall AJ. Self-administration of Metolazone reduces readmissions with decompensated congestive cardiac failure. Heart 1999; 82: 3978.
  • 10
    Felker GM, Adams KF Jr, Konstam MA, O'connor CM, Gheorghiade M. The problem of decompensated heart failure: nomenclature, classification, and risk stratification. Am Heart J 2003; 145 (2 Suppl.): S18S25.
  • 11
    Brater DC. Resistance to loop diuretics. Why it happens and what to do about it. Drugs 1985; 30: 42743.
  • 12
    Opasich C, Febo O, Riccardi PG et al. Concomitant factors of decompensation in chronic heart failure. Am J Cardiol 1996; 78: 3547.
  • 13
    Neuberg GW, Miller AB, O'Connor CM et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 2002; 144: 318.
  • 14
    Rector TS, Kubo SH, Cohn JN. Patient's self-assessment of their congestive heart failure Part 2: Content, reliability and validity of a new measure, the Minnesota Living with Heart Failure Questionnaire. Heart Failure 1987; 3: 198209.
  • 15
    Agarwal R, Gorski JC, Sundblad K, Brater DC. Urinary protein binding does not affect response to Furosemide in patients with nephritic syndrome. J Am Soc Nephrol 2000; 11: 11005.
  • 16
    Voelker JR, Cartwright-Brown D, Anderson S et al. Comparison of loop diuretics in patients with chronic renal insufficiency. Kidney Int 1987; 32: 5728.
  • 17
    Fogarty Y, Fraser CG, Browning MCK. Intra and inter individual variability of serum angiotensin converting enzyme activity: clinical implications. Ann Clin Biochem 1989; 26: 2012.
  • 18
    Hropot M, Sorgel F, Mutschler E. Pharmacodynamics and pharmacokinetics of Frusemide combinations with potassium retaining and thiazide like diuretics: clearance and micropuncture studies. Nauyn Schmiedebergs Arch Pharmacol 1986; 333: 45761.
  • 19
    Struthers AD, MacFadyen RJ, Fraser C et al. Non adherence to angiotensin converting enzyme inhibitor therapy: a comparison of different ways of measuring it in patients with chronic heart failure. J Am Coll Cardiol 1999; 34: 20727.
  • 20
    Brater DC, Chennavasin P, Day B, Burdette A, Anderson S. Bumetanide and Frusemide. Clin Pharmacol Ther 1983; 34: 20713.
  • 21
    Benet LZ. Pharmacokinetics/pharmacodynamics of Frusemide in man: a review. J Pharmacokin Biopharm 1979; 7: 127.
  • 22
    Grinstead WC, Francis MJ, Marks GF, Tawa CB, Zoghbi WA, Young JB. Discontinuation of chronic diuretic therapy in stable congestive heart failure secondary to coronary artery disease or to idiopathic dilated cardiomyopathy. Am J Cardiol 1994; 73: 8816.
  • 23
    Bennett SJ, Huster GA, Baker SL et al. Characterisation of the precipitants of hospitalization for heart failure. Am J Crit Care 1998; 7: 16874.
  • 24
    Khand AU, Gemmell I, Rankin AC, Cleland JG. Clinical events leading to progression of heart failure: insights from a national database. Eur Heart J 2001; 22: 15364.
  • 25
    Metcalfe C, Thompson SG, Cowie MR, Sharples LD. The use of hospital admission data as a measure of outcome in clinical studies of heart failure. Eur Heart J 2003; 24: 10512.
  • 26
    Vasko MR, Cartwright DB, Knochel JP, Nixon JV, Brater DC. Frusemide absorption altered in decompensated congestive heart failure. Ann Int Med 1985; 102: 31418.
  • 27
    Almeshari K, Ahlstrom NG, Capraro FE, Wilcox CS. A volume independent component to post diuretic sodium retention in humans. J Am Soc Nephrol 1993; 3: 187883.
  • 28
    Good JM, Brady AJ, Noormohammed FH, Oakley CM, Cleland JGF. Effect of intense angiotensin II suppression on the diuretic response to Frusemide during chronic ACE inhibition. Circulation 1994; 90: 2204.
  • 29
    MacFadyen RJ, Struthers AD. Diuretic use and abuse in systolic cardiac failure: a recipe for renal impairment? Heart 2000; 83: 468.
  • 30
    Struthers AD, Anderson G, Donnan P, MacDonald TM. Social deprivation increases cardiac hospitalisations in chronic heart failure independent of disease severity and diuretic non-adherence. Heart 2000; 83: 1216.
  • 31
    Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol 2003; 41: 21516.
  • 32
    Bauersachs J, Fraccarollo D, Ertl G, Gretz N, Wehling M, Christ M. Striking increase of natriuresis by low dose Spironolactone in congestive heart failure only in combination with ACE inhibition: mechanistic evidence to support RALES. Circulation 2000; 102: 23258.
  • 33
    Beck FX, Ohno A, Muller E, Seppi T, Pfaller W. Inhibition of angiotensin converting enzyme modulates structural and functional adaptation to loop diuretic induced diuresis. Kidney Int 1997; 57: 3643.
  • 34
    Rosenthal J, Boucher R, Nowaczynski W, Genest J. Acute changes in plasma volume, renin activity, and free aldosterone levels in healthy subjects following frusemide administration. Can J Physiol Pharmacol 1968; 46: 8591.